UBS Flags Underappreciated Missile Growth at Lockheed Martin

UBS upgraded Lockheed Martin to Buy from Neutral this week, arguing the market has badly underpriced the defense giant’s earnings trajectory. The bank lifted its 12-month price target to $674 from $581, implying roughly 26% upside, and the thesis rests on something more durable than a single earnings beat: accelerating missile and munitions production that Wall Street has largely overlooked while fixating on F-35 sustainment and program delays.

The numbers back up the contrarian call. Lockheed’s stock has lagged peers this year, weighed down by well-publicized F-16 and C-130 delivery delays that cost the company roughly $180 million combined in a recent quarter. But UBS argues that noise has obscured the real story: missiles and fire control revenue is expected to grow in the low-double-digits annually, driven by refilled Javelin, PAC-3, and HIMARS stockpiles after years of Ukraine and Middle East drawdowns, plus a $100 billion-plus order backlog that locks in years of future revenue regardless of near-term news cycles. For a company that generates roughly 95% of its revenue from government customers, that backlog visibility is worth far more than a headline miss.

For long-term investors, the setup is instructive. Lockheed pays a dividend yield near 2.3%, with a payout ratio that leaves ample room for continued increases, and trades at a valuation discount to peers despite comparable or better growth prospects once the temporary program hiccups roll off. The stock’s underperformance isn’t a verdict on the business — it’s a market pricing in execution risk that may already be resolving. Defense budgets across NATO and allied nations are structurally higher than they were five years ago, and that spending doesn’t reverse quickly once committed.

So what for long-term investors: this is a case study in separating short-term noise from long-term fundamentals. A stock lagging its sector isn’t automatically cheap, but when the lag is driven by fixable production delays rather than deteriorating demand, and when the order book already guarantees years of revenue, patient capital has historically been rewarded for looking past the discount.